---
title: Characteristics and Outcome of Patients With COVID-19 in ICUs in South Tyrol
nct_id: NCT05077319
overall_status: COMPLETED
sponsor: Institute of Mountain Emergency Medicine
study_type: OBSERVATIONAL
primary_condition: COVID-19
countries: Italy
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05077319.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05077319"
ct_last_update_post_date: 2021-10-14
last_seen_at: "2026-05-12T06:30:24.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Characteristics and Outcome of Patients With COVID-19 in ICUs in South Tyrol

**Official Title:** Characteristics and Outcome of Patients With COVID-19 Associated Respiratory Failure Treated in South Tyrol, Italy

**NCT ID:** [NCT05077319](https://clinicaltrials.gov/study/NCT05077319)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 550
- **Lead Sponsor:** Institute of Mountain Emergency Medicine
- **Collaborators:** Azienda Sanitaria dell'Alto Adige
- **Conditions:** COVID-19, COVID-19 Acute Respiratory Distress Syndrome
- **Start Date:** 2020-03-05
- **Completion Date:** 2021-10-04
- **CT.gov Last Update:** 2021-10-14

## Brief Summary

The investigators retrospectively investigate the epidemiology, clinical characteristics and therapeutic interventions of patients with COVID-19 associated respiratory failure admitted to the intensive care units in South Tyrol, Italy.

## Detailed Description

In this observational, retrospective study the epidemiology, characteristics, therapeutic interventions and outcome of patients with COVID-19 associated respiratory failure admitted to the intensive care units in South Tyrol, Italy, are assessed. Data extracted from the medical patients' records include type and duration of respiratory support (high-flow nasal oxygen, non-invasive ventilation, invasive ventilation), need for tracheostomy, vasopressor needs, antibiotic therapy, corticosteroid treatment, laboratory values (interleukin-6, C-reactive protein, procalcitonin, D-dimer, lymphocyte count), lengths of stay in the ICU and mortality.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* All patients admitted to the intensive care units in South Tyrol due to COVID-19 associated respiratory failure

Exclusion Criteria:

* SARS-CoV-2 patients admitted to the intensive care units in South Tyrol for other pathologies (i.e., not respiratory failure)
```

## Primary Outcomes

- **Mortality** _(time frame: Through study completion, an average of 1 year)_ — Mortality (dead/alive) at discharge from the ICU is defined as primary outcome

## Locations (1)

- Eurac research, Bolzano, Italy

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.eurac research|bolzano||italy` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05077319.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05077319*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*